Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Background: Pembrolizumab previously demonstrated robust antitumor activity and manageable safety in a phase Ib study of patients with heavily pretreated, programmed death ligand 1 (PD-L1)-positive, recurrent or metastatic nasopharyngeal carcinoma (NPC). The phase III KEYNOTE-122 study was conducted...
Saved in:
| 主要作者: | |
|---|---|
| 其他作者: | |
| 格式: | Article |
| 出版: |
2023
|
| 主題: | |
| 在線閱讀: | https://repository.li.mahidol.ac.th/handle/123456789/82374 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
| 機構: | Mahidol University |